2X1:ETR
Abivax SA
76,90 €
arrow_downward
-1,98%(-1,55) 1 d.
13. 10., 17:35:42 GMT+2 · EUR
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre 2X1…
Otvoriť
77,30 €
Vysoká
78,00 €
Nízka
75,90 €
Trh. kap.
6,74 mld.
Priem. obj.
1,79 tis.
Objem
2,48 tis.
Max. za 52 týž.
137,40 €
Min. za 52 týž.
60,85 €
Výnosy na akciu
-5,20 €
Počet zamestnancov
98
Otvoriť
77,30 €
Vysoká
78,00 €
Nízka
75,90 €
Trh. kap.
6,74 mld.
Priem. obj.
1,79 tis.
Objem
2,48 tis.
Max. za 52 týž.
137,40 €
Min. za 52 týž.
60,85 €
Výnosy na akciu
-5,20 €
Počet zamestnancov
98
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Idéal Investisseur
·
pred 4 hodinami
Abivax stock breaks below its 77.10 € support level despite Goldman Sachs buying recommendation
https://www.dars.gov.et/
·
pred 4 dňami
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Informácie o subjekte Abivax SA
Generálny riaditeľMarc de Garidel | Hartmut J. Ehrlich
Zamestnanci98
Dátum založenia4. 12. 2013
Hlavné sídlo-
Odvetvie-
Webabivax.com